Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?

Br J Haematol. 2023 Aug;202(4):725-727. doi: 10.1111/bjh.18915. Epub 2023 Jun 8.


Therapeutic options in immune-mediated thrombotic thrombocytopenic purpura (iTTP) during pregnancy are limited besides therapeutic plasma exchange (TPE) and corticosteroids. The report by Odetola et al. suggests that caplacizumab represents a reasonable option in iTTP during pregnancy, especially when the disease is not rapidly controlled with the standard TPE-corticosteroid association. Commentary on: Odetola et al. Safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura. Br J Haematol 2023;202:879-882.

Keywords: ADAMTS13; caplacizumab; pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura; therapeutic plasma exchange.

MeSH terms

  • ADAMTS13 Protein
  • Adrenal Cortex Hormones / therapeutic use
  • Female
  • Humans
  • Plasma Exchange
  • Pregnancy
  • Purpura, Thrombotic Thrombocytopenic* / drug therapy
  • Single-Domain Antibodies* / therapeutic use
  • von Willebrand Factor


  • caplacizumab
  • von Willebrand Factor
  • Single-Domain Antibodies
  • Adrenal Cortex Hormones
  • ADAMTS13 Protein